14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CLYM vs CAMP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (45.7/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 5–2 (led by Profitability & Quality), while CAMP wins 3–1 across the 6-pillar growth and valuation breakdown. CLYM trades at $9.63 (N/M Forward P/E, 0.0% operating margin) versus CAMP at $3.95 (N/M Forward P/E, -991.8% operating margin).
Growth vs. Quality Trade-Off: CLYM earns the overall head-to-head edge with a stronger Unified Composite Score (45.7/100 HOLD vs. CAMP 43.9/100 HOLD) and 1.52β · 112% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CLYM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs CAMP. Trailing 12-month operating profitability (CLYM 0.0% vs CAMP -991.8%) and valuation multiples (CLYM N/M vs CAMP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CLYM vs CAMP Key Questions & Quantitative Answers
As of Nov 17, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (45.7/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 5–2 (led by Profitability & Quality), while CAMP wins 3–1 across the 6-pillar growth and valuation breakdown. CLYM trades at $9.63 (N/M Forward P/E, 0.0% operating margin) versus CAMP at $3.95 (N/M Forward P/E, -991.8% operating margin). Growth vs. Quality Trade-Off: CLYM earns the overall head-to-head edge with a stronger Unified Composite Score (45.7/100 HOLD vs. CAMP 43.9/100 HOLD) and 1.52β · 112% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CLYM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CAMP leads the Growth & Scale pillar: CLYM posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CAMP at +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin). On trailing 12-month operating scale, CLYM generates N/A in USD-normalized revenue versus $5.3M for CAMP. In operating R&D and SG&A reinvestment, CLYM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAMP.
CAMP screens cheaper on headline valuation multiples. CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLYM (-29.3% ROE) versus CAMP (-146.1% ROE) capital efficiency.
In options market volatility and institutional positioning, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 112% Vol realized risk). By comparison, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.